PTEN and neoplasm: Interestingly, a metastatic NSCLC case with PTEN mutation, 80% PD-L1 expression and high tumor mutational load showed a durable response to temsirolimus (mTORC1 inhibitor), whereas treatment with anti-PD-1 antibodies induced rapid progression.